Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
30
EBS Quote, Financials, Valuation and Earnings
Last price:
$8.27
Seasonality move
:
-0.51%
Day range:
$7.95 - $8.35
52-week range:
$1.42 - $15.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
0.88x
Volume:
785.5K
Avg. volume:
1.1M
1-year change:
244.58%
Market cap:
$448.1M
Revenue:
$1B
EPS (TTM):
-$4.10
Analysts' Opinion
-
Consensus RatingEmergent BioSolutions has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.00, Emergent BioSolutions has an estimated upside of 45.1% from its current price of $8.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $8.27.
Fair Value
-
According to the consensus of 1 analyst, Emergent BioSolutions has 45.1% upside to fair value with a price target of $12.00 per share.
EBS vs. S&P 500
-
Over the past 5 trading days, Emergent BioSolutions has overperformed the S&P 500 by 1.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Emergent BioSolutions does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Emergent BioSolutions has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Emergent BioSolutions reported revenues of $283.8M.
Earnings Growth
-
Emergent BioSolutions has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Emergent BioSolutions reported earnings per share of $2.06.
Enterprise value:
960.8M
EV / Invested capital:
0.82x
Price / LTM sales:
0.40x
EV / EBIT:
--
EV / Revenue:
0.88x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
6.96x
Price / Operating cash flow:
3.18x
Enterprise value / EBITDA:
46.87x
Gross Profit (TTM):
$345.8M
Return On Assets:
-12.27%
Net Income Margin (TTM):
-19.08%
Return On Equity:
-35.94%
Return On Invested Capital:
-14.79%
Operating Margin:
22.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.4B | $1.1B | $1.1B | $264M | $283.8M | |
| Gross Profit | $712.9M | $335.4M | $345.8M | $87.2M | $161.2M | |
| Operating Income | $197M | -$206.3M | -$115.8M | -$23.9M | $64.5M | |
| EBITDA | $272.8M | -$527.9M | $20.5M | -$218.2M | $177.1M | |
| Diluted EPS | $0.55 | -$15.71 | -$4.10 | -$5.08 | $2.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $958.8M | $1.1B | $1.1B | $720.8M | $661.4M | |
| Total Assets | $2.6B | $2.9B | $2.9B | $1.9B | $1.5B | |
| Current Liabilities | $299.3M | $365.4M | $268.4M | $664M | $229.9M | |
| Total Liabilities | $1.4B | $1.3B | $1.5B | $1.2B | $969.4M | |
| Total Equity | $1.3B | $1.5B | $1.4B | $697.2M | $508.4M | |
| Total Debt | $879.4M | $848.9M | $1.1B | $861.8M | $662.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $201.2M | -$145.6M | $170.7M | $60M | $153.7M | |
| Cash From Investing | -$381.7M | $178.3M | $85.2M | -$18.9M | $112M | |
| Cash From Financing | $18.1M | -$187.3M | -$185.8M | -$43M | -$180.3M | |
| Free Cash Flow | $63.2M | -$209.4M | $138.1M | $47.4M | $147.9M | |
EBS
Sector
Market Cap
$448.1M
$45.9M
Price % of 52-Week High
54.77%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
244.58%
-32.15%
Beta (5-Year)
1.594
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$8.28
200-day SMA
Buy
Level
$7.21
Bollinger Bands (100)
Sell
Level
7.49 - 9.93
Chaikin Money Flow
Sell
Level
-100.2M
20-day SMA
Sell
Level
$8.75
Relative Strength Index (RSI14)
Sell
Level
42.46
ADX Line
Sell
Level
18.78
Williams %R
Neutral
Level
-58.0882
50-day SMA
Sell
Level
$9.21
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
273.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.5374)
Sell
CA Score
(Annual)
Level (-1.8882)
Buy
Beneish M-Score
(Annual)
Level (-3.5022)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.6379)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
Stock Forecast FAQ
In the current month, EBS has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EBS average analyst price target in the past 3 months is $12.00.
-
Where Will Emergent BioSolutions Stock Be In 1 Year?
According to analysts, the consensus estimate is that Emergent BioSolutions share price will rise to $12.00 per share over the next 12 months.
-
What Do Analysts Say About Emergent BioSolutions?
Analysts are divided on their view about Emergent BioSolutions share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Emergent BioSolutions is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Emergent BioSolutions's Price Target?
The price target for Emergent BioSolutions over the next 1-year time period is forecast to be $12.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EBS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Emergent BioSolutions is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of EBS?
You can purchase shares of Emergent BioSolutions via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Emergent BioSolutions shares.
-
What Is The Emergent BioSolutions Share Price Today?
Emergent BioSolutions was last trading at $8.27 per share. This represents the most recent stock quote for Emergent BioSolutions. Yesterday, Emergent BioSolutions closed at $8.27 per share.
-
How To Buy Emergent BioSolutions Stock Online?
In order to purchase Emergent BioSolutions stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
